INTRODUCTION {#s1}
============

In 1994, a positional cloning strategy revealed a unique rearrangement resulting from the fusion of the nucleophosmin (*NPM1*) gene, located on 5q35, to a previously unidentified protein tyrosine kinase gene located on 2p23 in an anaplastic large-cell lymphoma (ALCL) cell line ([@HOLLAMCS001115C106]). This new protein, called anaplastic lymphoma kinase (ALK), is expressed normally in the brain, small intestine, and testis, but not in the normal lymphoid cells ([@HOLLAMCS001115C106]). *ALK* shows the greatest sequence similarity to the insulin receptor subfamily of transmembrane tyrosine kinases. ALK contains an extracellular domain that has a low-density lipoprotein receptor domain class A (LDLa) region sandwiched between two meprin, A-5 protein, multiple receptor protein-tyrosine phosphatase mu (MAM) regions, followed by a glycine-rich region, a transmembrane region, and an intracellular domain containing a tyrosine kinase region. ALK is considered an orphan receptor, even though pleiotrophin (PTN) and midkine (MDK), both secreted growth factors, are known to bind and activate ALK downstream signaling ([@HOLLAMCS001115C150], [@HOLLAMCS001115C151]; [@HOLLAMCS001115C92]). PTN binding to ALK activates the mitogen-activated protein kinase (MAPK) pathway, whereas MDK binding to ALK induces insulin receptor substrate 1 (IRS1) phosphorylation, resulting in MAPK and phosphoinositide 3-kinase (PI3K) activation ([Fig. 1](#HOLLAMCS001115F1){ref-type="fig"}; [@HOLLAMCS001115C9]; [@HOLLAMCS001115C122]; [@HOLLAMCS001115C79]; [@HOLLAMCS001115C118]). However, studies that followed showed either no ligand binding activity of PTN and MDK to ALK ([@HOLLAMCS001115C104]; [@HOLLAMCS001115C95]) or that PTN\'s effect on ALK is not due to direct binding ([@HOLLAMCS001115C119]). Furthermore, a recent study shows longer heparin chains induce ALK dimerization, activation, and downstream signaling, indicating heparin serves as ALK\'s ligand or coligand ([@HOLLAMCS001115C109]).

![Anaplastic lymphoma kinase (ALK) signaling: Pathway figure that depicts normal activation of ALK through ligand binding. Receptor phosphorylation stimulates downstream signaling through the PI3K/AKT, MAPK/ERK, and STAT3 pathways. These signaling cascades can contribute to increased cancer cell growth, survival, and metastasis.](HollaMCS001115_F1){#HOLLAMCS001115F1}

ALK is thought to play a significant role in the development and function of the nervous system, where it controls the basic mechanisms of cell proliferation, survival, and differentiation in response to extracellular stimuli ([@HOLLAMCS001115C63]; [@HOLLAMCS001115C166]). The role of ALK in the development of model organisms, such as *Drosophila*, *Caenorhabditis elegans*, and zebrafish, has been well documented ([@HOLLAMCS001115C118]). In *Drosophila*, binding of a secreted protein ligand jelly belly (Jeb) activates dALK during synaptogenesis and organization of the visceral musculature of the gut ([@HOLLAMCS001115C89]; [@HOLLAMCS001115C127]). In *C. elegans*, ALK homolog, suppressor of constitutive dauer formation 2 (SCD-2) signals through the ligand hesitation behavior 1 (HEN-1) during neuromuscular junction development and regulates the dauer response to environmental stress ([@HOLLAMCS001115C86]; [@HOLLAMCS001115C125]). In zebrafish, leukocyte tyrosine kinase (Ltk), closely related to ALK, is required for the establishment of iridophores and mutations in *ltk* show defects in pigmentation patterns ([@HOLLAMCS001115C88]).

The most prevalent genomic *ALK* aberrations in human cancer are chromosomal rearrangements, resulting in fusion genes. *ALK* fusions arise from fusion of the 3′ half of ALK, derived from Chromosome 2 that retains its kinase catalytic domain, and the 5′ portion of a different gene that provides its promoter. Multiple different 5′ partners have been identified. Wild-type ALK is normally activated through binding of ligands to its extracellular domain, resulting in dimerization and autophosphorylation of the kinase domain. Structural studies show that fusion with multiple 5′ partners helps bypass this requirement and increase oncogenic potential of ALK, as evidenced by *NPM1-ALK* ([@HOLLAMCS001115C43]) and *EML4-ALK* ([@HOLLAMCS001115C162]) in non-small-cell lung cancer (NSCLC). Increased copy number and the presence of activating point mutations that result in kinase activation are also linked to oncogenic activity of *ALK*. These genetic alterations are found in multiple malignancies, including, but not limited to, lung cancer, neuroblastoma, rhabdomyosarcoma, renal cell carcinoma, inflammatory myofibroblastic tumor (IMT), and inflammatory breast cancer ([@HOLLAMCS001115C163]; [@HOLLAMCS001115C71]). Additionally, a recent report describes an alternative transcription initiation site leads to the detection of an oncogenic *ALK* isoform (*ALK*^*ATI*^) in 11% of melanomas and other tumor types ([@HOLLAMCS001115C165]). *ALK*^*ATI*^ arises independently of other *ALK* genomic alterations, and in vivo and in vitro studies show that *ALK*^*ATI*^-driven tumors are sensitive to crizotinib. Although activating mutations and copy-number changes of the *ALK* gene are currently being investigated for their role in tumor development and treatment response, the main clinical therapeutic implications of ALK lie in targeting of *ALK* fusions with tyrosine kinase inhibitors. In general, *ALK* fusions are mutually exclusive with mutations in *EGFR, KRAS*, and *ERBB2* genes, indicative of these genes' signaling through similar downstream pathways ([@HOLLAMCS001115C152]).

*ALK* MUTATIONS {#s2}
===============

Gain-of-function mutations of *ALK* are described primarily in neuroblastoma. In addition, thyroid ([@HOLLAMCS001115C110]) and lung cancers ([@HOLLAMCS001115C159]) have been shown to carry activating *ALK* point mutations. Most of the mutations are located in the kinase domain, including two hotspot mutations: F1174 (mutated to C, I, L, S, or V) and R1275 (mutated to Q and L) ([@HOLLAMCS001115C41]). These two hotspot mutations represent 85% of all *ALK* mutations. All reported *ALK* mutations could be classified into three groups: ligand-independent mutations (F1174I, F1174S, F1174L, and R1275Q), ligand-dependent mutations (D1091N, T1151M, and A1234T), and a kinase-dead mutation (I1250T) ([@HOLLAMCS001115C51]). *ALK* mutations are frequently acquired within an *ALK* fusion gene as a result of crizotinib resistance ([@HOLLAMCS001115C24]), alectinib resistance ([@HOLLAMCS001115C77]) in NSCLC, and lorlatinib resistance in ALCL ([@HOLLAMCS001115C103]). [Figure 2](#HOLLAMCS001115F2){ref-type="fig"} and [Table 1](#HOLLAMCS001115TB1){ref-type="table"} describe functionally characterized *ALK* mutations in the literature.

![Activating mutations in *ALK:* COSMIC (tumor only) frequencies of *ALK* mutations with published literature on functional and/or therapeutic significance. mRNA sequence depicts full reference sequence of *ALK* (NM_004304) with exon numbers marked. ALK protein sequence (0--1620 amino acids) shows different functional domains (MAM1, LDL, MAM2, Gly-rich, and kinase domain) with starting and ending amino acid numbers (UniProt). COSMIC frequency units (black circles and numbers in parentheses) refer to the number of tumor samples with a particular single-nucleotide variant (SNV) found in COSMIC. The SNVs without the black circles are referenced in literature that is not recorded in COSMIC.](HollaMCS001115_F2){#HOLLAMCS001115F2}

###### 

List of *ALK* mutations known to be oncogenic

  Alteration   Location                             Functional significance                              Tumor type      Reference(s)
  ------------ ------------------------------------ ---------------------------------------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  H694R        Extracellular                        Increased phosphorylation, promotes tumors in mice                   [@HOLLAMCS001115C159]
  K1062M       Juxtamembrane                        Transforms cells, promotes tumors in mice            Neuroblastoma   [@HOLLAMCS001115C21]; [@HOLLAMCS001115C110]
  G1128A       Kinase domain, glycine-rich region   Increased phosphorylation                            Neuroblastoma   [@HOLLAMCS001115C107]; [@HOLLAMCS001115C8]; [@HOLLAMCS001115C133]
  M1166R       Kinase domain                        Increased phosphorylation                            Neuroblastoma   [@HOLLAMCS001115C107]; [@HOLLAMCS001115C20]
  F1174I       Kinase domain                        Increased phosphorylation                            Neuroblastoma   [@HOLLAMCS001115C20]; [@HOLLAMCS001115C103]
  F1174L       Kinase domain                        Disrupts auto-inhibitory function                    Neuroblastoma   [@HOLLAMCS001115C21]; [@HOLLAMCS001115C46]; [@HOLLAMCS001115C35]; [@HOLLAMCS001115C132]; [@HOLLAMCS001115C10]; [@HOLLAMCS001115C55]; [@HOLLAMCS001115C77]; [@HOLLAMCS001115C62]; [@HOLLAMCS001115C169]
  F1174S       Kinase domain                        Ligand-independent activity                          Neuroblastoma   [@HOLLAMCS001115C94]
  L1198F       Kinase domain                        Increased phosphorylation                            Thyroid         [@HOLLAMCS001115C110]
  G1201E       Kinase domain                        Increased phosphorylation                            Thyroid, Skin   [@HOLLAMCS001115C110]
  F1245C       Kinase domain                        Increased phosphorylation                            Neuroblastoma   [@HOLLAMCS001115C133]; [@HOLLAMCS001115C62]
  R1275Q       Kinase domain                        Disrupts auto-inhibitory function                    Neuroblastoma   [@HOLLAMCS001115C21]; [@HOLLAMCS001115C46]; [@HOLLAMCS001115C35]; [@HOLLAMCS001115C3]; [@HOLLAMCS001115C17]
  E1384K       Kinase domain                        Increased phosphorylation                            Cervix          [@HOLLAMCS001115C159]

*ALK* Mutations in Neuroblastoma {#s2a}
--------------------------------

Gain-of-function mutations are reported in both familial and sporadic neuroblastoma patients ([@HOLLAMCS001115C46]; [@HOLLAMCS001115C64]). In familial neuroblastoma, *ALK* is a predisposition gene, and germline mutations have been found in 50% of familial neuroblastoma cases ([@HOLLAMCS001115C107]). Most frequent gain-of-function germline mutations of *ALK* are G1128A, R1192P, and R1275Q ([@HOLLAMCS001115C64]; [@HOLLAMCS001115C107]). However, in sporadic neuroblastoma, only 7% of cases show activating *ALK* mutations ([@HOLLAMCS001115C107]). Two hotspot mutations, F1174L and R1275Q, lead to ALK autophosphorylation and cytokine-independent growth ([@HOLLAMCS001115C21]; [@HOLLAMCS001115C64]). Furthermore, F1174L, the most recurrent mutation, predominantly occurs in *MYCN*-amplified tumors and potentiates *MYCN* oncogenic activity in neuroblastoma ([@HOLLAMCS001115C35]; [@HOLLAMCS001115C6]). In vitro and in vivo studies with cell lines expressing *ALK* mutations show different sensitivity to ALK inhibitors. Tumors expressing the R1275Q mutation are sensitive to crizotinib and TAE684, whereas F1174L mutant cells exhibit sensitivity to these agents only at higher doses ([@HOLLAMCS001115C46]; [@HOLLAMCS001115C10]).

*ALK* GENE REARRANGEMENTS {#s4}
=========================

*NPM1* was the first described fusion partner of *ALK* in 1994 in an ALCL cell line with a t(2;5) chromosomal rearrangement ([@HOLLAMCS001115C106]). Since then, several other *ALK* fusion partners have been described in multiple malignancies ([Table 2](#HOLLAMCS001115TB2){ref-type="table"}). The role of *ALK* gene rearrangements as oncogenic drivers has been well established in preclinical models including transgenic mouse models ([@HOLLAMCS001115C148]; [@HOLLAMCS001115C22]). In these models, ALK promotes the activation of downstream signaling pathways and other crucial aspects of malignant phenotypes like uncontrolled cellular proliferation and survival. The precise mechanisms that underlie the development of *ALK* gene rearrangements have yet to be elucidated. However, several steps are in play: the generation of double-strand DNA breaks, aberrant joining of the DNA ends, and selection of gene rearrangements that confer a survival advantage ([@HOLLAMCS001115C12]; [@HOLLAMCS001115C137]). In general, different *ALK* fusion partners affect ALK homodimerization, as well as ALK signaling potential. In fact, the comparison of a number of ALK fusion proteins has suggested differences in transforming and tumorigenic potential ([@HOLLAMCS001115C11]; [@HOLLAMCS001115C29]).

###### 

Known *ALK* chromosomal translocations that activate the tyrosine kinase domain

  Fusion         Chromosomal aberration   Tumor types      Reference(s)
  -------------- ------------------------ ---------------- --------------------------------------------------------------------------------------------------------------
  *ATIC-ALK*     Inv(2)(p23;q35)          ALCL             [@HOLLAMCS001115C28]; [@HOLLAMCS001115C2]
  *CAD-ALK*      Inv(2)(p23;p22)          CRC              [@HOLLAMCS001115C1]
  *CLTC-ALK*     t(2;17)(p23;q23)         IMT, ALCL, BCL   [@HOLLAMCS001115C11]; [@HOLLAMCS001115C29]; [@HOLLAMCS001115C36]; [@HOLLAMCS001115C96]; [@HOLLAMCS001115C19]
  *DCTN1-ALK*    t(2;12)(p23;q11)         IMT              [@HOLLAMCS001115C160]; [@HOLLAMCS001115C164]
  *EML4-ALK*     inv(2)(p21;p23)          NSCLC            [@HOLLAMCS001115C147]; [@HOLLAMCS001115C23]; [@HOLLAMCS001115C87]; [@HOLLAMCS001115C85]
  *FN1-ALK*      t(2)(p23;q34)            Ovarian, IMT     [@HOLLAMCS001115C126]; [@HOLLAMCS001115C117]
  *HIP1-ALK*     t(2;7)(p23;q11.23)       NSCLC            [@HOLLAMCS001115C40]; [@HOLLAMCS001115C56]; [@HOLLAMCS001115C115]
  *KIF5B-ALK*    t(2;10)(p23;p11)         Lung             [@HOLLAMCS001115C153]
  *KLC1-ALK*     t(2;14)(p23;q32.3)       Lung             [@HOLLAMCS001115C156]
  *NPM1-ALK*     t(2;5)(p23;q35)          NHL, ALCL        [@HOLLAMCS001115C106]; [@HOLLAMCS001115C123]; [@HOLLAMCS001115C118]
  *RANBP2-ALK*   Inv(2)(p23;q11--13)      IMT              [@HOLLAMCS001115C93]
  *SQSTM1-ALK*   t(2;5)(p23;q35)          BCL              [@HOLLAMCS001115C154]; [@HOLLAMCS001115C34]
  *STRN-ALK*     t(2)(p23;p22.2)          Thyroid          [@HOLLAMCS001115C72]
  *TFG-ALK*      t(2;3)(p23;q21)          ALCL             [@HOLLAMCS001115C53]; [@HOLLAMCS001115C54]
  *TPM3-ALK*     t(2;1)(p23;q25)          ALCL, IMT        [@HOLLAMCS001115C81]; [@HOLLAMCS001115C82]; [@HOLLAMCS001115C2]
  *TPM4-ALK*     t(2;19)(p23;q13.1)       ALCL, IMT        [@HOLLAMCS001115C82]; [@HOLLAMCS001115C98]

ALCL, anaplastic large-cell lymphoma; CRC, colorectal carcinoma; IMT, inflammatory myofibroblastic tumor; BCL, B-cell lymphoma; NSCLC, non-small-cell lung cancer; NHL, non-Hodgkin\'s lymphoma.

*ALK* Gene Rearrangements in Different Tumor Types {#s4a}
--------------------------------------------------

In the majority of ALCL cases, ALK is activated through chromosomal rearrangement ([@HOLLAMCS001115C97]). ALCL is a type of T-cell non-Hodgkin\'s lymphoma, and abnormalities of the *ALK* gene are common in this disease ([@HOLLAMCS001115C97]). As many as 50% of all adult cases of ALCL are ALK-positive, and up to 90% of all pediatric ALCL patients are ALK-positive ([@HOLLAMCS001115C50]; [@HOLLAMCS001115C33]). The most frequent translocation in ALCL is *NPM1-ALK*, accounting for ∼75%--80% of all ALK-positive ALCL ([@HOLLAMCS001115C123]). Additionally, *TPM3-ALK* has been found in 12%--18% of ALCL. Other fusion proteins are found at much lower frequency (\<2%), and include *TFG-ALK*, *CLTC1-ALK,* and *ATIC-ALK*. Importantly, 5-yr survival for ALK-positive ALCL patients is 70%--80%, as compared with 15%--45% for ALK-negative ALCL patients ([@HOLLAMCS001115C128]). In lung cancer, the *EML4-ALK* fusion was identified in 2007 NSCLCs in patients within NSCLC ([@HOLLAMCS001115C147]) and occurs at a frequency of ∼6.7% ([@HOLLAMCS001115C120]). This fusion is important diagnostically, as *EML4-ALK* is mutually exclusive with *EGFR* and *KRAS* mutations ([@HOLLAMCS001115C58]). Moreover, *ALK* rearrangements with constitutive kinase activity occur in 2%--7% of all NSCLCs, and are associated with young age, male gender, and no or light smoking history ([@HOLLAMCS001115C138]; [@HOLLAMCS001115C80]). More than a dozen different variants of *EML4-ALK* have been identified in NSCLC. Other less frequent ALK fusions identified in lung cancer are *SEC31A-ALK, HIP1-ALK, KIF5B-ALK,* and *KLC1-ALK*.

Inflammatory myofibroblastic tumors (IMTs) are soft-tissue mesenchymal neoplasms. Fifty percent of IMTs show chromosomal translocations involving the 2p23 region, resulting in *TPM3/4-ALK* fusions ([@HOLLAMCS001115C49]). Several other *ALK* fusion partners have been identified in IMT with \<5% frequency, including *TPM4* ([@HOLLAMCS001115C49]; [@HOLLAMCS001115C82]), *CLTC* ([@HOLLAMCS001115C11]), *CARS* ([@HOLLAMCS001115C29]), and *RANBP2* ([@HOLLAMCS001115C93]). *ALK* fusions are associated with better prognosis in IMT ([@HOLLAMCS001115C27]). In thyroid cancer, translocations involving *ALK* are detected in 2.2% of papillary thyroid cancer (PTC) patients ([@HOLLAMCS001115C25]). Various *ALK* fusions (*EML4-ALK, GFPT1-ALK, TFG-ALK,* and *STRN-ALK*) are reported in thyroid cancer patient tumors ([@HOLLAMCS001115C72]; [@HOLLAMCS001115C66]). Translocations of *ALK* identified by fluorescence in situ hybridization (FISH) show strong immunohistochemistry (IHC) positivity in these tumors.

In addition, *ALK* rearrangements occur in 10% of spitzoid tumors with *DCTN1-ALK* and *TPM3-ALK* being the most common ([@HOLLAMCS001115C13]; [@HOLLAMCS001115C164]). IHC confirms the expression of chimeric ALK protein, followed by downstream activation of AKT, ERK, and S6 proteins. Crizotinib is able to block these *ALK* fusion-induced downstream activities.

*ALK* COPY-NUMBER VARIANTS {#s6}
==========================

*ALK* gene amplification has been detected in variety of tumors (<http://cancergenome.nih.gov/>). In some reports, *ALK* gene amplification or increase in copy number due to polysomy of Chromosome 2 does not always correspond to the overexpression of ALK protein or increased downstream signaling. However, copy-number gain in NSCLC cell lines is associated with increased sensitivity to ALK inhibitors, such as crizotinib ([@HOLLAMCS001115C102]).

*ALK* Copy-Number Variants in Different Tumor Types {#s6a}
---------------------------------------------------

Neuroblastoma cell lines and primary neuroblastoma tissues show *ALK* gene amplification that correlates with ALK protein overexpression and promotion of tumorigenesis in neuroblastoma ([@HOLLAMCS001115C102]; [@HOLLAMCS001115C113]). Constitutively active ALK, due to gene amplification, results in hyper-phosphorylation of downstream SHCC protein in neuroblastoma cell lines ([@HOLLAMCS001115C102]). A follow-up in vitro study revealed phosphorylation of SHCC and other downstream activities (MAPK) were suppressed, which was associated with induction of apoptosis in neuroblastoma cell lines upon siRNA-mediated down-regulation of amplified *ALK*, suggesting targeting of ALK may be an appropriate therapeutic approach for tumors with *ALK* amplification ([@HOLLAMCS001115C113]). Likewise, *ALK* gene amplification was detected in 9.4% (8/85) of primary neuroblastoma tissues ([@HOLLAMCS001115C113]). FISH analysis showed *ALK* copy-number increase is a recurrent genetic event in neuroblastic tumors (39.1%, 96/245), however *ALK* gene amplification was seen at a lower frequency (1.2%, 3/246) in neuroblastomas ([@HOLLAMCS001115C161]). ALK protein expression by IHC (50.5%, 51/101) in these tumors is associated with a worsened patient prognosis.

A 2011 report revealed that a little more than 10% (11/107) of NSCLC patients exhibit *ALK* amplification and 63% (68/110) had copy-number gains, although it was observed in a small percentage of cells and was not associated with increased tissue expression of ALK, nor was it thought to be a significant tumor driving event for tumors ([@HOLLAMCS001115C130]). Another report characterized 191 patient samples and found 11% to have at least six copies of *ALK* ([@HOLLAMCS001115C170], *ASCO abstract \#10556*). In the same study, \>70% of NSCLC cell lines that gained three or four *ALK* copies also showed crizotinib sensitivity.

Amplification of *ALK* has been detected in ∼11% of esophageal cancer ([@HOLLAMCS001115C134]). However, there was no association of *ALK* amplification to either ALK protein expression or downstream phospho-STAT3 expression in these tumors. Copy-number gain of *ALK* was detected in 3.4% (26/756) ([@HOLLAMCS001115C4]) and 37% (25/68) ([@HOLLAMCS001115C121]) of colorectal cancer patients. Copy-number increase does not correlate with protein expression in the above studies, but was associated with poor prognosis and may predict lack of benefit from anti-EGFR treatment in colorectal cancer patients. *ALK* copy number increases due to polysomy of Chromosome 2 or its gene amplification has been reported in multiple breast cancer studies and correlates with poor prognosis. However, in most of the cases this does not correlate with increased protein expression as measured by IHC. Studies include amplification of *ALK* in 13.3% (130/980) of breast cancer patients ([@HOLLAMCS001115C146]), copy-number gain of *ALK* in 62% (82/133) of breast cancer cases ([@HOLLAMCS001115C52]), and copy-number gain of *ALK* in 47.2% (17/36) of inflammatory breast cancer ([@HOLLAMCS001115C75]). Mild increase in *ALK* copy number due to Chromosome 2 aneuploidy is reported in 64% (16/25) of inflammatory breast cancer cases ([@HOLLAMCS001115C78]). However, there was no increased ALK mRNA or protein expression in these tumors. Increased copy number, correlating with high ALK protein expression, has been reported in 25% of rhabdomyosarcoma cases and is associated with poor prognosis in rhabdomyosarcoma patients ([@HOLLAMCS001115C157]; [@HOLLAMCS001115C167]; [@HOLLAMCS001115C83]). In vitro studies show antitumor activity with ALK inhibitors in ALK-positive rhabdomyosarcoma cell lines ([@HOLLAMCS001115C158]; [@HOLLAMCS001115C99]).

THERAPEUTIC IMPLICATIONS {#s8}
========================

Therapeutic implications for *ALK* gene alterations are predominantly associated with *ALK* gene fusions, which predict tumor response to ALK inhibitors. Crizotinib, ceritinib, and recently alectinib are FDA approved for the treatment of patients with metastatic NSCLC whose tumors are positive for *ALK* fusions. Early phase 1 studies showed crizotinib yielded sustained responses in *ALK*-fusion-positive metastatic NSCLC patients ([@HOLLAMCS001115C80]; [@HOLLAMCS001115C139]; [@HOLLAMCS001115C16]). Two phase 3 studies, which led to FDA approval of crizotinib, further confirmed that crizotinib was superior to standard first-line pemetrexed + cisplatin chemotherapy in patients with previously untreated advanced *ALK*-rearranged NSCLC. In one study (PROFILE 1007), crizotinib showed overall response rate (ORR) of 65% as compared with 20% with either pemetrexed or docetaxel in patients who had failed one prior platinum-based regimen ([@HOLLAMCS001115C140]). In another study (PROFILE 1014), progression-free survival (PFS) and ORR were significantly improved with crizotinib than with first-line therapy with platinum-pemetrexed (median, 10.9 mo vs. 7 mo) ([@HOLLAMCS001115C149]). Furthermore, crizotinib was associated with disease control in *ALK*-fusion-positive NSCLC patients who had brain metastasis ([@HOLLAMCS001115C30]). In addition, crizotinib also showed therapeutic response in *ALK*-fusion-positive IMT patients ([@HOLLAMCS001115C14]) and pediatric patients with anaplastic large cell lymphoma and IMT ([@HOLLAMCS001115C108]).

Although crizotinib has shown excellent activity in patients with NSCLC who are *ALK*-fusion-positive, durable responses remain uncommon, with a median PFS of 13 mo, because of the development of resistance that leads to disease progression. Although the mechanism of resistance is still being delineated, acquired secondary mutations in the ALK kinase domain (F1174L, F1174C, L1196M, I1171T, G1202R, S1206Y, G1269S, and G1269A) or *ALK* gene amplification ([@HOLLAMCS001115C24]; [@HOLLAMCS001115C132]; [@HOLLAMCS001115C55]; [@HOLLAMCS001115C39]; [@HOLLAMCS001115C69]) are known to be associated with resistance. Resistance can also be mediated by activation of alternative ALK-independent survival pathways that hamper the effectiveness of crizotinib, including the epidermal growth factor pathway, insulin-like growth factor pathway, RAS/SRC signaling, and AKT/mTOR signaling, among others ([@HOLLAMCS001115C39]; [@HOLLAMCS001115C69]; [@HOLLAMCS001115C32]; [@HOLLAMCS001115C65]; [@HOLLAMCS001115C100]). [Tables 3](#HOLLAMCS001115TB3){ref-type="table"} and [4](#HOLLAMCS001115TB4){ref-type="table"} show *ALK* alterations that are either sensitive to ALK inhibitors ([Table 3](#HOLLAMCS001115TB3){ref-type="table"}) or resistant to ALK inhibitors ([Table 4](#HOLLAMCS001115TB4){ref-type="table"}).

###### 

Therapy-sensitive A*LK* alterations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (type)                      Sensitive variant(s)   Tumor type   Level of evidence^a^                                                 Reference(s)
  -------------------------------- ---------------------- ------------ -------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Crizotinib (ALK TKI)             Fusion                 NSCLC        1A                                                                   [@HOLLAMCS001115C80]; [@HOLLAMCS001115C16]; [@HOLLAMCS001115C140]; [@HOLLAMCS001115C149]

  RANBP2-ALK                       IMT                    3A           [@HOLLAMCS001115C14]                                                 

  NPM1-ALK\                        Neuroblastoma, lung    3B           [@HOLLAMCS001115C26]                                                 
  EMLA-ALK                                                                                                                                  

  F1174L\                          IMT                    3B           [@HOLLAMCS001115C90]; [@HOLLAMCS001115C37]                           
  R1275Q                                                                                                                                    

  Ceritinib (ALK TKI)              Fusion                 Lung         1A                                                                   [@HOLLAMCS001115C141]

  Fusion                           Thyroid                3A           [@HOLLAMCS001115C48]                                                 

  EML4-ALK/I1171T\                                        3B           [@HOLLAMCS001115C42]; [@HOLLAMCS001115C70]                           
  EML4-ALK/V1180L\                                                                                                                          
  EML4-ALK/L1196M\                                                                                                                          
  EML4-ALK/S1206Y\                                                                                                                          
  EML4-ALK/G1269A                                                                                                                           

  Alectinib (ALK TKI)              Fusion                 Lung         1A                                                                   [@HOLLAMCS001115C136]; [@HOLLAMCS001115C44]

  Amplification                    Neuroblastoma          3B           [@HOLLAMCS001115C129]                                                

  L1196M\                          NSCLC                  3B           [@HOLLAMCS001115C129]; [@HOLLAMCS001115C77]; [@HOLLAMCS001115C168]   
  G1269A\                                                                                                                                   
  C1156Y\                                                                                                                                   
  F1174L\                                                                                                                                   
  1151Tins\                                                                                                                                 
  L1152R                                                                                                                                    

  EML4-ALK/1151Tins\               NSCLC                  3B           [@HOLLAMCS001115C129]; [@HOLLAMCS001115C77]                          
  EML4-ALK/L1152R\                                                                                                                          
  EML4-ALK/C1156Y\                                                                                                                          
  EML4-ALK/F1174L\                                                                                                                          
  EML4-ALK/L1196M\                                                                                                                          
  EML4-ALK/S1206Y\                                                                                                                          
  EML4-ALK/G1269A                                                                                                                           

  Lorlatinib (ALK TKI)             NPM1-ALK/C1156F\       ALCL         3B                                                                   [@HOLLAMCS001115C103]
                                   NPM1-ALK/I1171T\                                                                                         
                                   NPM1-ALK/I1171N\                                                                                         
                                   NPM1-ALK/F1174I\                                                                                         
                                   NPM1-ALK/N1178H\                                                                                         
                                   NPM1-ALK/E1201K\                                                                                         
                                   NPM1-ALK/D1203N                                                                                          

  F1174L\                          Neuroblastoma          3B           [@HOLLAMCS001115C62]                                                 
  F1245C\                                                                                                                                   
  R1275Q                                                                                                                                    

  1151Tins\                                               3B           [@HOLLAMCS001115C67]; [@HOLLAMCS001115C169]                          
  C1156T\                                                                                                                                   
  L1196M\                                                                                                                                   
  G1202R\                                                                                                                                   
  G1269A                                                                                                                                    

  EML4-ALK/L1196M\                 Lung                   3B           [@HOLLAMCS001115C169]                                                
  EML4-ALK/G1269A                                                                                                                           

  Brigatinib (ALK TKI)             EML4-ALK/L1196M\       NSCLC        3B                                                                   [@HOLLAMCS001115C68]; [@HOLLAMCS001115C18]
                                   NPM1-ALK/L1196Q                                                                                          

  ASP3026 (ALK TKI)                NPM1-ALK               ALCL         3B                                                                   [@HOLLAMCS001115C47]

  EML4-ALK/L1196M                  NSCLC                  3B           [@HOLLAMCS001115C105]                                                

  Entrectinib (ALK TKI)            EML4-ALK\              Colorectal   3B                                                                   [@HOLLAMCS001115C1], [@HOLLAMCS001115C84]
                                   CAD-ALK                                                                                                  

  X-396 (ALK TKI)                  EML4-ALK/C1156Y\       Lung         3B                                                                   [@HOLLAMCS001115C90]
                                   EML4-ALK/L1196M                                                                                          

  F1174L\                          Neuroblastoma          3B           [@HOLLAMCS001115C37]                                                 
  R1275Q                                                                                                                                    

  Retaspimycin (HSP90 inhibitor)   EML4-ALK               NSCLC        3A                                                                   [@HOLLAMCS001115C135]; [@HOLLAMCS001115C112]

  Tanespimycin (HSP90 inhibitor)   EML4-ALK/V1180L        NSCLC        3B                                                                   [@HOLLAMCS001115C70]

  NPM1-ALK\                        ALCL                   3B           [@HOLLAMCS001115C7]                                                  
  TPR-ALK                                                                                                                                   

  RANBP2-ALK/F1174L                IMT                    3B           [@HOLLAMCS001115C132]                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only clinically available drugs are listed in the table.

TKI, tyrosine kinase inhibitor; NSCLC, non-small-cell lung cancer; NB, neuroblastoma; ALCL, anaplastic large-cell lymphoma; IMT, inflammatory myofibroblastic tumor; CRC, colorectal cancer.

^a^Definition of level of evidence based on [@HOLLAMCS001115C101].

###### 

Therapy resistant *ALK* alterations

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (type)            Resistant variant(s)     Tumor type   Level of evidence^a^                                                                                             Reference(s)
  ---------------------- ------------------------ ------------ ---------------------------------------------------------------------------------------------------------------- --------------------------------------------
  Crizotinib (ALK TKI)   Amplification-EML4-ALK   NSCLC        3A                                                                                                               [@HOLLAMCS001115C39]

  1151insT\              NSCLC                    3A           [@HOLLAMCS001115C24]; [@HOLLAMCS001115C39]; [@HOLLAMCS001115C69]; [@HOLLAMCS001115C116]; [@HOLLAMCS001115C169]   
  L1152R\                                                                                                                                                                       
  C1156Y\                                                                                                                                                                       
  F1174V\                                                                                                                                                                       
  G1202R\                                                                                                                                                                       
  S1206Y\                                                                                                                                                                       
  G1269A                                                                                                                                                                        

  EML4-ALK/1151insT\                              3B           [@HOLLAMCS001115C24]; [@HOLLAMCS001115C39]; [@HOLLAMCS001115C69]; [@HOLLAMCS001115C116]; [@HOLLAMCS001115C169]   
  EML4-ALK/L1152R\                                                                                                                                                              
  EML4-ALK/C1156Y\                                                                                                                                                              
  EML4-ALK/L1196M\                                                                                                                                                              
  EML4-ALK/L1198P\                                                                                                                                                              
  EML4-ALK/D1203N                                                                                                                                                               

  NPM1-ALK               ALCL                     3B           [@HOLLAMCS001115C18]                                                                                             

  RANBP2-ALK             IMT                      3A           [@HOLLAMCS001115C132]                                                                                            

  Ceritinib (ALK TKI)    EML4-ALK/1151Tins\                    3B                                                                                                               [@HOLLAMCS001115C42]
                         EML4-ALK/L1152R\                                                                                                                                       
                         EML4-ALK/C1156Y\                                                                                                                                       
                         EML4-ALK/F1174C\                                                                                                                                       
                         EML4-ALK/G1202R                                                                                                                                        

  Alectinib (ALK TKI)    EML4-ALK/I1171Tins\      NSCLC        3B                                                                                                               [@HOLLAMCS001115C70]; [@HOLLAMCS001115C77]
                         EML4-ALK/V1180L\                                                                                                                                       
                         EML4-ALK/G1202R                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only clinically available drugs are listed in the table.

TKI, tyrosine kinase inhibitor; NSCLC, non-small-cell lung cancer; NB, neuroblastoma; ALCL, anaplastic large-cell lymphoma; IMT, inflammatory myofibroblastic tumor; CRC, colorectal cancer.

^a^Definition of level of evidence based on [@HOLLAMCS001115C101].

Even though different resistance mechanisms are being discovered, most crizotinib-resistant tumors continue to depend on ALK signaling and are sensitive to more potent, structurally distinct, second-generation ALK inhibitors, such as ceritinib, alectinib, brigatinib, and lorlatinib. A preclinical study showed alectinib was able to block the resistant gatekeeper mutation (L1196M) in *ALK*-fusion-positive NSCLC cells ([@HOLLAMCS001115C129]). Two phase 1/2 studies showed alectinib was well tolerated. The first study conducted in ALK inhibitor-naïve patients with *ALK*-rearranged NSCLC showed objective response of 93.5% (43 of 46) that included two patients with complete response and 41 patients with partial response ([@HOLLAMCS001115C136]). Another study that tested efficacy of alectinib in patients with crizotinib-resistant *ALK-*rearranged NSCLC showed objective response of 55% (24 of 44), with a confirmed complete response (CR) in one patient and confirmed partial response (PR) in 14 patients ([@HOLLAMCS001115C44]). In a multicenter phase 2 study in crizotinib-resistant *ALK*-fusion-positive NSCLC patients, alectinib showed a 48% response rate with 33 of 69 patients demonstrating confirmed PRs ([@HOLLAMCS001115C143]).

In preclinical studies, ceritinib efficiently inhibits several ALK secondary mutations developed in the setting of crizotinib therapy ([@HOLLAMCS001115C42]). In a phase 1 study, 114 *ALK*-rearranged, crizotinib-naïve (80) and -resistant (34) NSCLC patients received ceritinib ([@HOLLAMCS001115C141]). The overall response rate was 58%, with one patient achieving a CR, 65 patients a PR, and 25 patients with stable disease. This study also had six of seven patients with a confirmed response who carried *ALK* gene amplification or mutations (L1196M, S1206Y) after crizotinib therapy. In another phase 1 study with 20 *ALK*-rearranged patients (19 NSCLC and 1 IMT) ceritinib treatment resulted in an ORR of 55% ([@HOLLAMCS001115C111]). A recent multicenter phase 1 study (ASCEND-1) tested the activity of ceritinib in 246 *ALK*-rearranged NSCLC patients ([@HOLLAMCS001115C76]). The ORR was 72% (60 of 83 ALK inhibitor \[ALKi\] naïve patients) and 56% (92 of 163 ALK inhibitor pretreated patients). A still ongoing phase 2 (ASCEND-2) study that evaluated ceritinib activity in 140 *ALK*-rearranged NSCLC patients who failed crizotinib in addition to other regimens showed investigator assessed RR of 38.6% ([@HOLLAMCS001115C31]).

Brain metastasis is a common problem in advanced NSCLC patients and 10%--40% NSCLC patients develop brain metastasis during the course of their disease ([@HOLLAMCS001115C60]). Brain metastasis occurs in 30%--50% of *ALK*-positive NSCLC patients who are naïve to ALK inhibitors ([@HOLLAMCS001115C38]; [@HOLLAMCS001115C145]; [@HOLLAMCS001115C124]). Despite the inability of most of the chemotherapy regimens to cross the blood--brain barrier, pemetrexed treatment in NSCLC patients shows some effectiveness against brain metastasis ([@HOLLAMCS001115C5]). Crizotinib has shown systemic and intracranial disease control in NSCLC patients that are *ALK*-positive ([@HOLLAMCS001115C30]). However, crizotinib-resistant patients develop new or show progression of preexisting intracranial lesions ([@HOLLAMCS001115C30]). Recent studies showed that second-generation agents ceritinib ([@HOLLAMCS001115C74]; [@HOLLAMCS001115C31]), alectinib ([@HOLLAMCS001115C44]; [@HOLLAMCS001115C143]), and brigatinib ([@HOLLAMCS001115C73]) are active in intracranial diseases.

Clinical data with crizotinib, ceritinib, and alectinib showed that G1202R is a common ALK resistance mutation. However, there are other mutations that differ in sensitivity to the various anti-ALK kinase inhibitors ([Table 4](#HOLLAMCS001115TB4){ref-type="table"}). Several next-generation ALK inhibitors are being developed to treat previously treated ALK inhibitor resistant mutations. The list includes brigatinib ([@HOLLAMCS001115C61]; [@HOLLAMCS001115C144]), lorlatinib ([@HOLLAMCS001115C45]; [@HOLLAMCS001115C142]), and X-396 ([@HOLLAMCS001115C37]). Both brigatinib and lorlatinib inhibit several known resistant mutations, and lorlatinib showed effective inhibition against the G1202R mutation ([@HOLLAMCS001115C45]). These results suggest that understanding the resistance mechanism and selecting the appropriate tyrosine kinase inhibitor (TKI) may be required to optimize response to therapy. Interestingly, a preclinical study showed that the inhibition of autophagy with chloroquine may restore crizotinib sensitivity ([@HOLLAMCS001115C65]).

In addition to targeting ALK directly, there are pharmacological strategies that allow for its indirect targeting. Specifically, there has been some success with inhibiting ALK indirectly by targeting heat-shock proteins, namely HSP90, in lung cancer. Inhibition of HSP90, a chaperone protein that stabilizes a wide variety of proteins, including ALK, has shown some preclinical efficacy in crizotinib-resistant *ALK* fusions (*EML4-ALK* and *NPM1-ALK*), including secondary resistant mutants in lung cancer models ([@HOLLAMCS001115C131]). In addition, several drug combinations, including ALK inhibitors and other receptor tyrosine kinase (RTK) inhibitors or HSP90 inhibitors, are being explored in preclinical/clinical studies: IGF1R ([@HOLLAMCS001115C91]); MEK ([@HOLLAMCS001115C155]; [@HOLLAMCS001115C32]; [@HOLLAMCS001115C59]); and HSP90 ([@HOLLAMCS001115C131]). As recent preclinical data indicate, the immune checkpoint proteins are induced in ALK-positive NSCLC tumors ([@HOLLAMCS001115C114]; [@HOLLAMCS001115C57]); thus, combination therapies of checkpoint (PD-1/PD-L1, CTLA-4) and ALK inhibitors are being explored in the clinical setting for ALK-positive NSCLC patients (NCT02393625, NCT01998126).

Chemotherapy also remains a viable option in patients with *ALK* translocations. In terms of chemotherapy for NSCLC, pemetrexed-based chemotherapy may be more effective than other nonpemetrexed combinations ([@HOLLAMCS001115C15]).

CONCLUSIONS {#s9}
===========

*ALK* rearranged tumors represent a specific subset of tumors that can be effectively targeted with currently available ALK inhibitors. Hence testing for *ALK* alterations in tumors known to have this molecular aberration is now an obligatory part of the diagnosis. FISH, next-generation sequencing (NGS) of tumor tissue, and sequencing of circulating tumor cells offer alternative and often complementary ways of detecting tumors with *ALK* alterations. The almost inevitable emergence of resistance during TKI therapy requires rebiopsy of the tumor at relapse to identify resistance mechanisms that could be targeted with newer ALK inhibitors and other novel therapeutic strategies, including HSP90 inhibitors and pemetrexed-based chemotherapy. Checkpoint inhibitors either as single agents or combination with ALK inhibitors are being evaluated in clinical trials.
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